Company intelligence / Profile preview
Houston Gene Therapeutics
United Stateshoustongenetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
HGT-Cardio-1, their lead product, has shown 80% inhibition of atherosclerosis in animal models compared to an average of 27% inhibition with statins in the same model. The company is raising funds to advance HGT-Cardio-1 through IND toward clinical trials.
- Therapeutic areas
- OncologyCardiovascularOther
- Modalities
- AAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Houston Gene Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Houston Gene Therapeutics.